Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

This article is part of our Design special report previewing Milan Design Week.

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa ...

After a near-fatal bike crash in April 2024, ultrarunner David Roche decided to go all in chasing big goals. Five months ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide ...

Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

Just a few weeks before Selena was murdered on March 31, 1995, producer Guy Roche went to record with the Queen of Tejano for ...